Cybin Secures New U.S. Patent for DMT-Based Anxiety Treatment Program, Bolstering Phase 2 Clinical Development Cybin Inc. (CYBN), a company advancing next-generation mental health treatments using psychedelics, has been granted a new U.S. patent supporting its CYB004 pro

#CYBN strengthens its psychedelic therapeutics pipeline with a newly granted U.S. patent for its DMT-based anxiety treatment program — a major step forward as it advances into Phase 2 clinical development.
#CybinInc
prismmarketview.com/cybin-secure...

Cybin Welcomes FDA’s Embrace of Psychedelic Therapeutics as a Mental Health Priority FDA Commissioner Calls for Innovation in Mental Health Treatments Cybin Inc. (NYSE: CYBN), a clinical-stage neuropsychiatry company developing next-generatio

#CYBN celebrates FDA’s focus on psychedelic therapeutics as a mental health priority! Promising advancements in treatments for depression and anxiety are on the horizon.
#CybinInc
#Psychedelics #MentalHealth #Biotech prismmarketview.com/cybin-welcom...